EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Improved outcomes of localized diffuse large B‐cell lymphoma at the Waldeyer ring in comparison to the sinonasal area in the rituximab era

Wei-Li Ma iD, Ruey-Long Hong, Pei-Jen Lou, Ming Yao, Shang-Ju Wu, Chung-Wu Lin iD, Chun-Wei Wang, Chin-Hao Chang, Ann-Lii Cheng, Sung-Hsin Kuo iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.6851 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Wei-Li Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Rituximab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taiwan, National Taiwan University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse large B‐cell lymphoma (DLBCL) of the head‐and‐neck area primarily involves the Waldeyer ring (WR) and sinonasal area (SN). However, the differential clinical outcomes between patients with WR‐DLBCL and those with SN‐DLBCL in the rituximab era remain unclear.

Methods

To avoid confounding factors contributed by advanced DLBCL with WR and SN involvement, we assessed the clinical outcomes of patients with stage I/II WR‐DLBCL and SN‐DLBCL and compared them with those having corresponding stages of DLBCL in the lymph nodes but without other extranodal involvement (LN‐DLBCL) in the same period. We compared the patients' clinical characteristics, treatment modalities, event‐free survival (EFS), and overall survival (OS) among the three subgroups.

Results

We analyzed 67, 15, and 106 patients with WR‐DLBCL, SN‐DLBCL, and LN‐DLBCL, respectively, between January 2000 and December 2019. All patients received front‐line rituximab‐based regimens, and > 80% received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone‐based regimens. More patients with SN‐DLBCL had revised International Prognostic Index (R‐IPI) score 3 (27%) when compared with those with WR‐DLBCL (7%) and those with LN‐DLBCL (10%, p = 0.181). Patients with WR‐DLBCL, LN‐DLBCL, and SN‐DLBCL had 5‐year EFS and OS rates of 80.7%, 59.5%, and 41.9% ( p = 0.021) and 83.7%, 70.8%, and 55.8% ( p = 0.032), respectively. Compared to patients with LN‐DLBCL, those with WR‐DLBCL also had a significantly favorable 5‐year EFS rate ( p = 0.021) and 5‐year OS rate ( p = 0.023). Three of the 15 patients with SN‐DLBCL experienced lymphoma recurrence in the brain after front‐line treatment. In multivariate analyses, R‐IPI scores of 1–2 and 3 served as significantly poor prognostic factors for patients with poor EFS and OS.

Conclusions

Compared to patients with LN‐DLBCL, patients with WR‐DLBCL receiving front‐line rituximab‐based treatments had favorable clinical outcomes; however, patients with SN‐DLBCL had worse clinical outcomes. Further studies on molecular prognostic factors and treatment strategies for SN‐DLBCL are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseRituximabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultVincristineAged, 80 and overDoxorubicinRetrospective StudiesCyclophosphamideNeoplasm StagingTreatment OutcomeYoung AdultPrognosisParanasal Sinus Neoplasms

Stichwörter der Autor:innen

DLBCLR‐IPI scoreTaiwanWaldeyer ringextranodalprognosissinonasal area

Substanzen

RituximabVincristineDoxorubicinCyclophosphamide

Autor:innen und Institutionen

  • Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
  • Cancer Research Center, National Taiwan University College of Medicine, Taipei City, Taiwan.
  • Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei City, Taiwan.
  • Department of Medical Oncology, National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei City, Taiwan.
  • Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.

ORCID-Profile: Wei-Li Ma, Chung-Wu Lin, Sung-Hsin Kuo

Förderung

  • National Science and Technology Council, Taiwan
  • National Taiwan University Hospital

Zitieren

APA

Ma, W. L., Hong, R. L., Lou, P. J., Yao, M., Wu, S. J., Lin, C. W., Wang, C. W., Chang, C. H., Cheng, A. L., & Kuo, S. H. (2024). Improved outcomes of localized diffuse large B‐cell lymphoma at the Waldeyer ring in comparison to the sinonasal area in the rituximab era. Cancer Medicine. https://doi.org/10.1002/cam4.6851

Vancouver

Ma WL, Hong RL, Lou PJ, Yao M, Wu SJ, Lin CW, et al. Improved outcomes of localized diffuse large B‐cell lymphoma at the Waldeyer ring in comparison to the sinonasal area in the rituximab era. Cancer Medicine. 2024. doi:10.1002/cam4.6851

BibTeX
@article{Ma2024,
  author = {Ma, Wei-Li and Hong, Ruey-Long and Lou, Pei-Jen and Yao, Ming and Wu, Shang-Ju and Lin, Chung-Wu and Wang, Chun-Wei and Chang, Chin-Hao and Cheng, Ann-Lii and Kuo, Sung-Hsin},
  title = {Improved outcomes of localized diffuse large B‐cell lymphoma at the Waldeyer ring in comparison to the sinonasal area in the rituximab era},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6851}
}
Kostenlos starten →